Format

Send to

Choose Destination
F1000Res. 2018 Mar 12;7:307. doi: 10.12688/f1000research.13179.1. eCollection 2018.

Renal cell carcinoma: a review of biology and pathophysiology.

Author information

1
Division of Medical Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA.

Abstract

Over the past decade, our understanding of the biology and pathophysiology of renal cell carcinoma (RCC) has improved significantly. Insight into the disease process has helped us in developing newer therapeutic approaches toward RCC. In this article, we review the various genetic and immune-related mechanisms involved in the pathogenesis and development of this cancer and how that knowledge is being used to develop therapeutic targeted drugs for the treatment of RCC. The main emphasis of this review article is on the most common genetic alterations found in clear cell RCC and how various drugs are currently targeting such pathways. This article also looks at the role of the immune system in allowing the growth of RCC and how the immune system can be manipulated to reactivate cytotoxic immunity against RCC.

KEYWORDS:

BAP-1; Glutaminase; HIF; Immunotherapy; PBRM-1; VHL; biology; mTOR; renal cell carcinoma; von Hippel Lindau

Conflict of interest statement

Competing interests: ETL receives kidney cancer clinical trial funding from Argos, Bristol-Myers Squibb, Calithera, Genentech, Merck, Peloton, Pfizer, and Roche; has served as a consultant for Bristol-Myers Squibb; and serves on the Independent Data Monitoring Board for Calithera. ERK receives kidney cancer clinical trial funding from Bristol-Myers Squibb. TWF receives clinical trial funding from Bristol-Myers Squibb, Novartis, Pfizer, Bavarian Nordic, Cougar Biotechnology, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Genentech, Roche, Exelixis, Aragon Pharmaceuticals, Sotio, Tokai Pharmaceuticals, Astra-Zeneca/MedImmune, Lilly, Astellas, Agensys, and Seattle Genetics and has served as a consultant for GTx.No competing interests were disclosed.No competing interests were disclosed.

Publication type

Publication type

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center